Removal of intact β2-microglobulin at neutral ph by using seed-conjugated polymer beads prepared with β2-microglobulin-derived peptide (58-67)

Biotechnology Progress

Volumn 27, Issue 2, 2011, Pages 521-529

  Kang, Sungsoo ^a   Yang, Jee Eun ^a   Kim, Jehoon ^a   Ahn, Minkoo ^a   Koo, Hee Jung ^a   Kim, Mira ^a   Lee, Yoon Sik ^a   Paik, Seung R ^a  

^a Seoul National University   (South Korea)

Author keywords

2 microglobulin; 2 microglobulin removal; Amyloid fibril formation; Dialysis related amyloidosis; Kidney dysfunction; Seed conjugated polymer bead

Indexed keywords

AMYLOID FIBRIL FORMATION; AMYLOIDOGENESIS; BEAD SURFACE; BINDING CAPACITIES; BLOOD CIRCULATION; CARBOXYLIC GROUP; CHARGE INTERACTIONS; CLINICAL APPLICATION; CONTINUOUS FLOWS; DIALYSIS-RELATED AMYLOIDOSIS; HIGH SPECIFICITY; ITS EFFICIENCIES; KIDNEY DYSFUNCTION; MOLECULAR SELF ASSEMBLY; N-TERMINALS; NEUTRAL PH; PEPTIDE FIBRILS; POLYMER BEADS; REMOVAL SYSTEMS; RENAL FAILURE;

AMINO ACIDS; BLOOD; DIALYSIS; DISEASES; GLYCOPROTEINS; PEPTIDES; RESINS; SEED;

CONJUGATED POLYMERS;

BETA 2 MICROGLOBULIN; MICROSPHERE; PEPTIDE FRAGMENT;

AMYLOIDOSIS; ARTICLE; BLOOD; EVALUATION; HUMAN; ISOLATION AND PURIFICATION; KIDNEY DISEASE; PH; RENAL REPLACEMENT THERAPY; TECHNIQUE;

AMYLOIDOSIS; BETA 2-MICROGLOBULIN; HUMANS; HYDROGEN-ION CONCENTRATION; KIDNEY DISEASES; METHODS; MICROSPHERES; PEPTIDE FRAGMENTS; RENAL DIALYSIS;

EID: 79954421258     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.562     Document Type: Article

References (63)

1. Bjorkman PJ, Saper MA, Samraoui B. Structure of the human class I histocompatibility antigen, HLA-A2. Nature. 1987; 329: 506-512.
2. Pamer E, Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol. 1998; 16: 323-358.
3. Saper MA, Bjorkman PJ, Wiley DC. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 Å resolution. J Mol Biol. 1991; 219: 277-319.
4. Trinh CH, Smith DP, Kalverda AP, Phillips SEV, Radford SE. Crystal structure of monomeric human β-2-microglobulin reveals clues to its amyloidogenic properties. Proc Natl Acad Sci USA. 2002; 99: 9771-9776.
5. Gorevic PD, Casey TT, Stone WJ, DiRaimondo CR, Prelli FC, Frangione B. Beta-2 microglobulin is an amyloidogenic protein in man. J Clin Invest. 1985; 76: 2425-2429.
6. Floege J, Ehlerding G. Beta-2-microglobulin-associated amyloidosis. Nephron. 1996; 72: 9-26.
7. Jadoul M, Drueke T, Zingraff J, Ypersele de Strihou C. Does dialysis-related amyloidosis regress after transplantation? Nephrol Dial Transplant. 1997; 12: 655-657.
8. Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J. Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. Kidney Int. 1991; 39: 1012-1019.
9. Aoike I, Gejyo F, Arakawa M. Learning from the Japanese Registry: how will we prevent long-term complications? Niigata Research Programme for beta2-M removal membrane. Nephrol Dial Transplant. 1995; 10: 7-15.
10. Fry AC, Singh DK, Chandna SM, Farrington K. Relative importance of residual renal function and convection in determining beta-2-microglobulin levels in high-flux haemodialysis and on-line haemodiafiltration. Blood Purif. 2007; 25: 295-302.
11. Gejyo F, Yamada T, Odani S, Nakagawa Y, Arakawa M, Kunitomo T, Kataoka H, Suzuki M, Hirasawa Y, Shirahama T, Cohen AS, Schmid K. A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin. Biochem Biophys Res Commun. 1985; 129: 701-706.
12. Gejyo F, Odani S, Yamada T, Honma N, Saito H, Suzuki Y, Nakagawa Y, Kobayashi H, Maruyama Y, Hirasawa Y, Suzuki M, Arakawa M. Beta2-microglobulin: a new form of amyloid protein associated with chronic hemodialysis. Kidney Int. 1986; 30: 385-390.
13. Zhou XJ, Rakheja D, Yu X, Saxena R, Vaziri ND, Silva FG. The aging kidney. Kidney Int. 2008; 74: 710-720.
14. Saito A, Gejyo F. Current clinical aspects of dialysis-related amyloidosis in chronic dialysis patients. Ther Apher Dial. 2006; 10: 316-320.
15. Gejyo F. β2-Microglobulin amyloid. Amyloid. 2000; 7: 17-18.
16. Bardin T, Kuntz D, Zingraff J. Synovial amyloidosis in patients undergoing long-term hemodialysis. Arthritis Rheum. 1985; 28: 1052-1058.
17. Kleinman KS, Cobrn JW. Amyloid syndrome associated with hemodialysis. Kidney Int. 1989; 35: 567-575.
18. Koch KM. Dialysis-related amyloidosis. Kidney Int. 1992; 41: 1416-1429.
19. Kuntz D, Naveau B, Bardin T, Drueke T, Treves R, Dryll A. Destructive spondylarthropathy in hemodialyzed patients. Arthritis Rheum. 1984; 27: 369-375.
20. Drüeke TB. Dialysis-related amyloidosis. Nephrol Dial Transplant. 1998; 13: 58-64.
21. Dobson CM. Protein folding and misfolding. Nature. 2003; 426: 884-890.
22. Rochet J-C, Lansbury PT. Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol. 2000; 10: 60-68.
23. Uversky VN, Fink AL. Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim Biophys Acta. 2004; 1698: 131-153.
24. McParland VJ, Kad NM, Kalverda AP, Brown A, Kirwin-Jones P, Hunter MG, Sunde M, Radford SE. Partially unfolded states of β2-microglobulin and amyloid formation in vitro. Biochemistry. 2000; 39: 8735-8746.
25. Naiki H, Hashimoto N, Suzuki S, Kimura H, Nakakuki K, Gejyo F. Establishment of a kinetic model of dialysis-related amyloid fibril extension in vitro. Amyloid. 1997; 4: 223-232.
26. Platt GW, McParland VJ, Kalverda AP, Homans SW, Radford SE. Dynamics in the unfolded state of β2-microglobulin studied by NMR. J Mol Biol. 2005; 346: 279-294.
27. Morgan CJ, Gelfand M, Atreya C, Miranker AD. Kidney dialysis-associated amyloidosis: a molecular role for copper in fiber formation. J Mol Biol. 2001; 309: 339-345.
28. Yamamoto S, Hasegawa K, Yamaguchi I, Tsutsumi S, Kardos J, Goto Y, Gejyo F, Naiki H. Low concentrations of sodium dodecyl sulfate induce the extension of β2-microglobulin-related amyloid fibrils at a neutral pH. Biochemistry. 2004; 43: 11075-11082.
29. Yamamoto S, Yamaguchi I, Hasegawa K, Tsutsumi S, Goto Y, Gejyo F, Naiki H. Glycosaminoglycans enhance the trifluoroethanol-induced extension of β2-microglobulin-related amyloid fibrils at a neutral pH. J Am Soc Nephrol. 2004; 15: 126-133.
30. Kihara M, Chatani E, Sakai M, Hasegawa K, Naiki H, Goto Y. Seeding-dependent maturation of β2-microglobulin amyloid fibrils at neutral pH. J Biol Chem. 2005; 280: 12012-12018.
31. Myers L, Jones S, Jahn TR, Morten IJ, Tennent GA, Hewitt EW, Radford SE. A systematic study of the effect of physiological factors on β2-microglobulin amyloid formation at neutral pH. Biochemistry. 2006; 45: 2311-2321.
32. Connors LH, Shirahama T, Skinner M, Fenves A, Cohen AS. In vitro formation of amyloid fibrils from intact beta-2-microglobulin. Biochem Biophys Res Commun. 1985; 131: 1063-1068.
33. Jones S, Smith DP, Radford SE. Role of the N and C-terminal strands of beta 2-microglobulin in amyloid formation at neutral pH. J Mol Biol. 2003; 330: 935-941.
34. Ronco C, Nissenson AR. Does nanotechnology apply to dialysis? Blood Purif. 2001; 19: 347-352.
35. Humes HD, Fissell WH, Tiranathanagul K. The future of hemodialysis membranes. Kidney Int. 2006; 69: 1115-1119.
36. Fissell WH, Humes HD, Fleischman AJ, Roy S. Dialysis and nanotechnology: now, 10 years, or never? Blood Purif. 2007; 25: 12-17.
37. Bowry SK. Nano-controlled membrane spinning technology: regulation of pore size, distribution and morphology of a new polysulfone dialysis membrane. Contrib Nephrol. 2002; 137: 85-94.
38. Gejyo F, Homma N, Hasegawa S, Arakawa M. A new therapeutic approach to dialysis amyloidosis: intensive removal of β2-microglobulin with adsorbent column. Artif Organs. 1993; 17: 240-243.
39. Kutsuki H. β2-Microglobulin-selective direct hemoperfusion column for the treatment of dialysis-related amyloidosis. Biochim Biophys Acta. 2005; 1753: 141-145.
40. Lornoy W, Becaus I, Billiouw JM, Sierens L, Van Malderen P, D'Haenens P. On-line haemodiafiltration. Remarkable removal of β2-microglobulin. Long-term clinical observations. Nephrol Dial Transplant. 2000; 15: 49-54.
41. Ypersele De Strihou C. β2-Microglobulin amyloidosis: effect of ESRF treatment modality and dialysis membrane type. Nephrol Dial Transplant. 1996; 11: 147-149.
42. Shabunina IV, Afanas'eva OI, Pokrovskii SN. Immunosorbent for removal of β2-microglobulin from human blood plasma. Bull Exp Biol Med. 2001; 132: 984-986.
43. Grovender EA, Kellogg B, Singh J, Blom D, Ploegh H, Wittrup KD, Langer RS, Ameer GA. Single-chain antibody fragment-based adsorbent for the extracorporeal removal of β2-microglobulin. Kidney Int. 2004; 65: 310-322.
44. Stamopoulos D, Benaki D, Bouziotis P, Zirogiannis PN. In vitro utilization of ferromagnetic nanoparticles in hemodialysis therapy. Nanotechnology. 2007; 18: 495102.
45. Stamopoulos D, Bouziotis P, Benaki D, Kotsovassilis C, Zirogiannis PN. Utilization of nanobiotechnology in haemodialysis: mock-dialysis experiments on homocysteine. Nephrol Dial Transplant. 2008; 23: 3234-3239.
46. Stamopoulos D, Bouziotis P, Benaki D, Zirogiannis PN, Kotsovassilis K, Belessi V, Dalamagas V, Papadopoulos K. Magnetically assisted haemodialysis for the prevention of dialysis-related amyloidosis. Ther Apher Dial. 2009; 13: 34-41.
47. Vanholder R, Argilés A, Baumeister U, et al. Uremic toxicity: present state of the art. Int J Artif Organs. 2001; 24: 695-725.
48. Saito A, Kazama JJ, Iino N, Cho K, Sato N, Yamazaki H, Oyama Y, Takeda T, Orlando RA, Shimizu F, Tabata Y, Gejyo F. Bioengineered implantation of megalin-expressing cells: a potential intracorporeal therapeutic model for uremic toxin protein clearance in renal failure. J Am Soc Nephrol. 2003; 14: 2025-2032.
49. Kaiser E, Colescott RL, Bossinger CD, Cook PI. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem. 1970; 34: 595-598.
50. Fernandez-Escamilla AM, Rousseau F, Schymkowitz J, Serrano L. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol. 2004; 22: 1302-1306.
51. Guglielmi F, Monti DM, Arciello A, Torrassa S, Cozzolino F, Pucci P, Relini A, Piccoli R. Enzymatically active fibrils generated by the self-assembly of the ApoA-I fibrillogenic domain functionalized with a catalytic moiety. Biomaterials. 2009; 30: 829-835.
52. Kelly SM, Jess TJ, Price NC. How to study proteins by circular dichroism. Biochim Biophys Acta. 2005; 1751: 119-139.
53. Kim H, Cho JK, Chung W-J, Lee YS. Core-shell-type resins for solid-phase peptide synthesis: comparison with gel-type resins in solid-phase photolytic cleavage reaction. Org Lett. 2004; 6: 3273-3276.
54. Kim D-H, Lee HY, Kim H, Kim H, Lee YS, Park SB. Quantitative evaluation of hicore resin for the nonspecific binding of proteins by on-bead colorimetric assay. J Comb Chem. 2006; 8: 280-285.
55. Kozhukh GV, Hagihara Y, Kawakami T, Hasegawa K, Naiki H, Goto Y. Investigation of a peptide responsible for amyloid fibril formation of β2-microglobulin by achromobacter protease I. J Biol Chem. 2002; 277: 1310-1315.
56. Ohhashi Y, Hagihara Y, Kozhukh G, Hoshino M, Hasegawa K, Yamaguchi I, Naiki H, Goto Y. The intrachain disulfide bond of β2-microglobulin is not essential for the immunoglobulin fold at neutral pH, but is essential for amyloid fibril formation at acidic pH. J Biochem. 2003; 131: 45-52.
57. Hasegawa K, Ohhashi Y, Yamaguchi I, Takahashi N, Tsutsumi S, Goto Y, Gejyo F, Naiki H. Amyloidogenic synthetic peptides of β2-microglobulin-a role of the disulfide bond. Biochem Biophys Res Commun. 2003; 304: 101-106.
58. Jones S, Manning J, Kad NM, Radford SE. Amyloid-forming peptides from β2-microglobulin-insights into the mechanism of fibril formation in vitro. J Mol Biol. 2003; 325: 249-257.
59. Platt GW, Routledge KE, Homans SW, Radford SE. Fibril growth kinetics reveal a region of β2-microglobulin important for nucleation and elongation of aggregation. J Mol Biol. 2008; 378: 251-263.
60. Ivanova MI, Gingery M, Whitson LJ, Eisenberg D. Role of the C-terminal 28 residues of β2-microglobulin in amyloid fibril formation. Biochemistry. 2003; 42: 13536-13540.
61. Ivanova MI, Sawaya MR, Gingery M, Attinger A, Eisenberg D. An amyloid-forming segment of β2-microglobulin suggests a molecular model for the fibril. Proc Natl Acad Sci USA. 2004; 101: 10584-10589.
62. Ivanova MI, Thompson MJ, Eisenberg D. A systematic screen of β2-microglobulin and insulin for amyloid-like segments. Proc Natl Acad Sci USA. 2006; 103: 4079-4082.
63. Daugirdas JT, Blake PG, Ihg TS, editors. Handbook of Dialysis. Philadelphia: Lippincott Williams & Wilkins; 2007.